CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash Flows From Operating Activities:
Net Loss	$ (44,799)	$ (2,533)	$ (36,525)
Adjustments to Reconcile Net Loss to Cash Used in Operating Activities:
Depreciation and Amortization	2,248	2,718	2,583
Amortization of Intangible Assets	1,913	3,143	949
Amortization and Premium of Marketable Securities	17	(14)
Realized Loss (Gain) on Sales and Maturities of Marketable Securities	5	(4)	24
(Gain) Loss on Sale or Disposal of Assets	(58)	(38)	(556)
Stock-Based Compensation Expense	2,342	2,802	3,058
Non-Cash Interest Expense	307	728	181
Non-Cash Tax Benefit			(529)
Changes in Operating Assets and Liabilities, Net of Acquisitions:
Accounts and Other Receivables	154	220	1,283
Prepaid and Other Current Assets	241	(546)	743
Other Assets	34	5,592	722
Accounts Payable and Accrued Expenses	2,076	(1,193)	(2,463)
Deferred Revenue		(39,382)	(2,038)
Other Liabilities	(138)	(1,865)	2,699
Net Cash Used in Operating Activities	(35,658)	(30,372)	(29,869)
Cash Flows From Investing Activities:
Cash Acquired in the CuraGen acquisition			51,654
Sales and Maturities of Marketable Securities	51,003	42,383	2,674
Purchases of Marketable Securities	(52,717)	(56,522)	(9,559)
Acquisition of Property and Equipment	(509)	(2,100)	(528)
Proceeds from Sale or Disposal of Assets	68	77	850
Net Cash (Used in) Provided by Investing Activities	(2,155)	(16,162)	45,091
Cash Flows From Financing Activities:
Net Proceeds from Stock Issuances	36,023	1,014	668
Related Party Loan Due to Medarex			(2,957)
Issuance of Term Loan	5,000	10,000
Payment of Convertible Subordinated Debt	(12,503)
Payment of Other Liabilities	(86)	(197)	(176)
Net Cash Provided by (Used in) Financing Activities	28,434	10,817	(2,465)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(9)	2	(12)
Net (Decrease) Increase in Cash and Cash Equivalents	(9,388)	(35,715)	12,745
Cash and Cash Equivalents at Beginning of Period	21,287	57,002	44,257
Cash and Cash Equivalents at End of Period	11,899	21,287	57,002
Supplemental Disclosure of Non-Cash Flow Information
Shares Issued to Executive Officers			250
Supplemental Disclosure of Cash Flow Information
Cash Paid for Interest	$ 1,560	$ 604	$ 157